Cellectis Shares Advance After FDA Grants RMAT Designation for CAR-T Candidate
Cellectis SA shares climbed about 5% in premarket trading following U.S. Food and Drug Administration granting Regenerative Medicine Advanced Therapy designation to its allogeneic CAR-T candidate lasmecabtagene timgedleucel for relapsed or refractory B-cell acute lymphoblastic leukemia. The designation cites Phase 1 BALLI-01 data supporting efficac…